Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)
EU Regulation 2016/1179 · Adopted 19 July 2016 · Extends to United Kingdom
Commission Regulation (EU) 2016/1179
of 19 July 2016
amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006f1, and in particular Article 37(5) thereof,
Whereas:
(1)
Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EECf2.
(2)
Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.
(3)
Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.
(4)
With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.
(5)
With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.
(6)
Regulation (EC) No 1272/2008 should be amended accordingly.
(7)
Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Councilf3, those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Councilf4 or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Councilf5.
(8)
In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.
(9)
The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,
HAS ADOPTED THIS REGULATION:
Annotations to the whole text
Footnotes
- f1
- f2
-
Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).
- f3
-
Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).
- f4
-
Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).
- f5
-
Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).
Contents
1
Regulation (EC) No 1272/2008 is amended as follows:
- (1)
Annex VI is amended in accordance with the Annex to this Regulation;
- (2)
in Annex VI, Table 3.2 is deleted.
2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall apply from 1 March 2018.
Article 1(2) shall apply from 1 June 2017.
By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
Signature
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 July 2016.
For the Commission
The President
Jean-Claude Juncker
Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
- (a)
the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;
- (b)
the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:
Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-035-00-8 pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate 245-430-1 23103-98-2 Carc. 2
Acute Tox. 3
Acute Tox. 3
Skin Sens. 1
Aquatic Acute 1 Aquatic Chronic 1
H351
H331
H301
H317
H400
H410
GHS08
GHS06
GHS09
Dgr
H351
H331
H301
H317
H410
M = 10
M = 100’
‘029-002-00-X dicopper oxide;
copper (I) oxide
215-270-7 1317-39-1 Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H302
H318
H410
M = 100’ ‘602-020-00-0 1,2-dichloropropane;
propylene dichloride
201-152-2 78-87-5 Flam. Liq. 2
Carc. 1B
Acute Tox. 4*
Acute Tox. 4*
H225
H350
H332
H302
GHS02
GHS08
GHS07
Dgr
H225
H350
H332
H302’
‘602-033-00-1 chlorobenzene 203-628-5 108-90-7 Flam. Liq. 3
Acute Tox. 4
Skin Irrit. 2
Aquatic Chronic 2
H226
H332
H315
H411
GHS02
GHS07
GHS09
Wng
H226
H332
H315
H411’
‘603-055-00-4 propylene oxide;
1,2-epoxypropane; methyloxirane
200-879-2 75-56-9 Flam. Liq. 1
Carc. 1B
Muta. 1B
Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Irrit. 2
H224
H350
H340
H331
H311
H302
H335
H319
GHS02
GHS08
GHS06
Dgr
H224
H350
H340
H331
H311
H302
H335
H319’
‘604-030-00-0 bisphenol A;
4,4′-isopropylidenediphenol
201-245-8 80-05-7 Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1
H360F
H335
H318
H317
GHS08
GHS05 GHS07
Dgr
H360F
H335
H318
H317’
‘604-092-00-9 phenol, dodecyl-, branched; [1]
phenol, 2-dodecyl-, branched; [2]
phenol, 3-dodecyl-, branched; [3]
phenol, 4-dodecyl-, branched; [4]
phenol, (tetrapropenyl) derivatives [5]
310-154-3 [1]
[2]
[3]
[4]
[5]
121158-58-5 [1]
[2]
[3]
210555-94-5 [4]
74499-35-7 [5]
Repr. 1B
Skin Corr. 1C
Eye Dam. 1
Aquatic Acute 1 Aquatic Chronic 1
H360F
H314
H318
H400
H410
GHS08
GHS05
GHS09
Dgr
H360F
H314
H410
M = 10
M = 10’
‘605-013-00-0 chloralose (INN);
(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral
240-016-7 15879-93-3 Acute Tox. 4*
Acute Tox. 3
STOT SE 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H336
H400
H410
GHS06
GHS09
Dgr
H332
H301
H336
H410
M = 10
M = 10
C’ ‘605-022-00-X glutaral; glutaraldehyde;
1,5-pentanedial
203-856-5 111-30-8 Acute Tox. 2
Acute Tox. 3
STOT SE 3
Skin Corr. 1B
Resp. Sens. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2
H330
H301
H335
H314
H334
H317
H400
H411
GHS06
GHS05
GHS08
GHS09
Dgr
H330
H301
H335
H314
H334
H317
H410
EUH071 STOT SE 3; H335: 0,5 % ≤ C < 5 %
M = 1’
‘606-014-00-9 chlorophacinone (ISO);
2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione
223-003-0 3691-35-8 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,1 %
STOT RE 2; H373 (blood):
0,01 % ≤ C < 0,1 %
M = 1
M = 1’
‘606-021-00-7 N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone 212-828-1 872-50-4 Repr. 1B
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
H360D***
H335
H315
H319
GHS08
GHS07
Dgr
H360D***
H335
H315
H319
STOT SE 3; H335: C ≥ 10 %’ ‘607-056-00-0 warfarin (ISO);
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]
(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]
(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]
201-377-6
[1]
226-907-3
[2]
226-908-9
[3]
81-81-2 [1]
5543-57-7
[2]
5543-58-8
[3]
Repr. 1A
Acute Tox. 1
Acute Tox. 1
Acute Tox. 2
STOT RE 1
Aquatic Chronic 2
H360D
H330
H310
H300
H372 (blood)
H411
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H411
Repr. 1A; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,5 %
STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’
‘607-059-00-7 coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin 227-424-0 5836-29-3 Repr. 1B
Acute Tox. 2
Acute Tox. 3
Acute Tox. 2
STOT RE 1
Aquatic Chronic 1
H360D
H330
H311
H300
H372 (blood)
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H311
H300
H372 (blood)
H410
Repr. 1B; H360D: C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 1,0 %
STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %
M = 10’
‘607-157-00-X difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin 259-978-4 56073-07-5 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 10
M = 10’
‘607-172-00-1 brodifacoum (ISO);
4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin
259-980-5 56073-10-0 Repr. 1A
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1A; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 10
M = 10’
‘607-375-00-5 flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin 421-960-0 90035-08-8 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,05 %
STOT RE 2; H373 (blood):
0,005 % ≤ C < 0,05 %
M = 10
M = 10’
‘607-623-00-2 diisobutyl phthalate 201-553-2 84-69-5 Repr. 1B H360Df GHS08
Dgr
H360Df’ ‘613-166-00-X flumioxazin (ISO);
2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione
— 103361-09-7 Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410
M = 1 000
M = 1 000’
‘613-121-00-4 chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide 265-268-5 64902-72-3 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1 000
M = 100’
‘616-011-00-4 N,N-dimethylacetamide 204-826-4 127-19-5 Repr. 1B
Acute Tox. 4*
Acute Tox. 4*
H360D***
H332
H312
GHS08
GHS07
Dgr
H360D***
H332
H312’
‘616-037-00-6 acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide 251-899-3 34256-82-1 Carc. 2
Repr. 2
Acute Tox. 4
STOT SE 3
STOT RE 2
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H361f
H332
H335
H373 (kidney)
H315
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361f
H332
H335
H373 (kidney)
H315
H317
H410
M = 1 000
M = 100’
‘616-207-00-X polyhexamethylene biguanide hydrochloride;
PHMB
— 32289-58-0
27083-27-8
Carc. 2
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H351
H330
H302
H372 (respiratory tract) (inhalation)
H318
H317
H400
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H330
H302
H372 (respiratory tract) (inhalation)
H318
H317
H410
M = 10
M = 10’
- (c)
the following entries are inserted in accordance with the order of the index numbers:
Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘005-020-00-3 disodium octaborate anhydrous; [1]
disodium octaborate tetrahydrate [2]
234-541-0 [1]
234-541-0 [2]
12008-41-2 [1]
12280-03-4 [2]
Repr. 1B H360FD GHS08
Dgr
H360FD’ ‘014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08
Dgr
H350i A’ ‘014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08
Wng
H351 (inhalation) A’ ‘029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400
H410
GHS09
Wng
H410 EUH032 M = 10’ ‘029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 100’ ‘029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H400
H410
GHS06
GHS09
Dgr
H332
H301
H410
M = 10’ ‘029-018-00-7 tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]
215-582-3 [1]
215-582-3 [2]
1333-22-8 [1]
12527-76-3 [2]
Acute Tox. 4
Aquatic Acute 1 Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
M = 10’ ‘029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H319
H400
H410
GHS06
GHS09
Dgr
H331
H302
H319
H410
M = 10’ ‘029-020-00-8 copper(II) carbonate--copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H319
H400
H410
GHS07
GHS09
Wng
H332
H302
H319
H410
M = 10’ ‘029-021-00-3 copper dihydroxide;
copper(II) hydroxide
243-815-9 20427-59-2 Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H318
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H318
H410
M = 10’ ‘029-022-00-9 bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide
— 8011-63-0 Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H318
H410
M = 10’ ‘029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
M = 10’ ‘082-013-00-1 lead powder;
[particle diameter < 1 mm]
231-100-4 7439-92-1 Repr. 1A
Lact.
H360FD
H362
GHS08
Dgr
H360FD
H362
Repr. 1A; H360D: C ≥ 0,03 %’ ‘082-014-00-7 lead massive:
[particle diameter ≥ 1 mm]
231-100-4 7439-92-1 Repr. 1A
Lact.
H360FD
H362
GHS08
Dgr
H360FD
H362’
‘605-040-00-8 hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]
4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]
3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]
- [1]
250-863-4 [2]
257-187-9 [3]
130066-44-3 [1]
31906-04-4 [2]
51414-25-6 [3]
Skin Sens. 1A H317 GHS07
Wng
H317’ ‘607-716-00-8 bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one 249-205-9 28772-56-7 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):
0,0005 % ≤ C < 0,005 %
M = 1
M = 1’
‘607-717-00-3 difethialone (ISO);
3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one
— 104653-34-1 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
EUH070 Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 100
M = 100’
‘607-718-00-9 perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts 206-801-3 [1]
[2]
[3]
375-95-1 [1]
21049-39-8 [2]
4149-60-4 [3]
Carc. 2
Repr. 1B
Lact.
Acute Tox. 4
Acute Tox. 4
STOT RE 1
Eye Dam. 1
H351
H360Df
H362
H332
H302
H372 (liver, thymus, spleen)
H318
GSH08
GSH07
GHS05
Dgr
H351
H360Df
H362
H332
H302
H372 (liver, thymus, spleen)
H318’
‘607-719-00-4 dicyclohexyl phthalate 201-545-9 84-61-7 Repr. 1B
Skin Sens. 1
H360D
H317
GHS08
GHS07
Dgr
H360D
H317’
‘608-067-00-3 3,7-dimethylocta-2,6-dienenitrile 225-918-0 5146-66-7 Muta. 1B H340 GHS08
Dgr
H340’ ‘612-288-00-0 bupirimate (ISO);
5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate
255-391-2 41483-43-6 Carc. 2
Skin Sens. 1B
Aquatic Chronic 1
H351
H317
H410
GHS08
GHS07
GHS09
Wng
H351
H317
H410
M = 1’ ‘612-289-00-6 triflumizole (ISO);
(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine
— 68694-11-1 Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H302
H373 (liver)
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H360D
H302
H373 (liver)
H317
H410
M = 1
M = 1’
‘616-218-00-X benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide — 1072957-71-1 Acute Tox. 3
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H400
H410
GHS06
GHS09
Dgr
H331
H301
H410
M = 100
M = 100’
‘616-219-00-5 fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide — 658066-35-4 Aquatic Chronic 2 H411 GHS09 H411’ ‘616-220-00-0 pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea 266-096-3 66063-05-6 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1
M = 1’
‘617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08
Wng
H341’